Resumo

DRNOVSEK, M.; ECHIN, M.; ERCOLANO, M.  e  RUBIN, Z.. Prevention and treatment of osteoporosis in multiple myeloma, early stages of breast cancer and prostate cancer. Rev. argent. endocrinol. metab. [online]. 2011, vol.48, n.2, pp.107-113. ISSN 1851-3034.

The aim of this review is to discuss recent findings in the physiopathology and treatment of osteoporotic lesions present in almost all patients with MM. The efficacy of bisphosphonates is well known, so we summarize the current treatment schedules according to the most recent consensus. Pamidronate and Zoledronate are equally effective and universally accepted. They should be administered intravenously on a monthly basis for two years. Oral clodronate is accepted in Europe but not in USA. Even if bisphosphonates provide a better quality of life, they do not increase survival. Because osteonecrosis of the jaw has been repeatedly reported after high doses of bisphosphonates, we discuss the necessary precautions to prevent this condition emphasizing frequent dental care and examinations.

Palavras-chave : Lytic lesions; Zoledronate; Pamidronate.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )